7 results about "Dextran Derivatives" patented technology

The invention belongs to the technical field of flocculants, and particularly provides a wastewater treatment flocculant and a preparation method thereof.The preparation method of the wastewater treatment flocculant comprises the following steps that 1, guar gum and isopropyl acrylamide react to prepare a precursor A; guar gum reacts with sodium methacrylate to prepare a precursor material B; and 2) uniformly mixing deionized water, the precursor material A, the precursor material B and a glucan derivative polymer, then adding a monomer and an initiator, and carrying out a photo-initiation reaction, purification and drying to obtain the flocculant. The prepared flocculant has the advantages of good flocculation effect and applicability to a complex sewage system.

An adhesive composition includes a beta-1,3-glucan derivative having an acyl group introduced in a beta-1,3-glucan, and a petroleum-based resin. An adhesive tape (1) is provided with an adhesive layer (3) formed of the adhesive composition.

The application discloses a temozolomide dexchlorpheniramine derivative and application thereof in preparation of an antitumor drug, and is based on new cognition of a TMZ drug resistance mechanism, designs and synthesizes two temozolomide derivatives. The target compounds retain the alkylating activity of TMZ, and metabolites do not produce 5-amino-imidazole-4 amide (AICA), but produce dexchlorpheniramine derivatives of AICA. Thus, the TMZ chemotherapy sensitivity is enhanced, and the TMZ drug resistance of glioma is delayed or reversed. The application first reconstructs the TMZ molecule from the metabolic product level, breaks through the action mode of the inherent drug resistance, and provides a brand-new drug design idea for overcoming the TMZ drug resistance. A new generation of TMZ derivative drugs can be developed, a single drug or a combined treatment scheme with higher efficacy and lower drug resistance is realized, and more breakthrough treatment options are provided for GBM patients.

Disclosed herein is a method of treating a surface. Such a method can comprise at least: (a) providing a liquid composition comprising at least a solvent, antimicrobial agent, and alpha-glucan derivative, and (b) contacting the liquid composition with a surface, thereby providing antimicrobial activity to the surface. Further disclosed are compositions comprising various alpha-glucan derivatives, and applications of using these derivatives.

A laundry care or dish care composition can include a poly alpha-1,6-glucan derivative, wherein the poly alpha-1,6-glucan derivative includes: (i) a poly alpha-1,6-glucan backbone of glucose monomer units; and (ii) at least one hydrophobic organic group linked to the poly alpha-1,6-glucan backbone through an ether (—O—) linkage moiety; wherein, the poly alpha-1,6-glucan backbone has a weight average degree of polymerization of at least 5; wherein, the poly alpha-1,6-glucan derivative has a degree of substitution of ether linkage moiety of from 0.20 to 1.00; wherein the poly alpha-1,6-glucan derivative is substantially free from hydrophilic substitution.

The application provides a modified dextran, a T1 weighted iron-based contrast agent and a preparation method and application thereof. The modified dextran template has a general structure (I), and the preparation method comprises the following steps: esterification reaction of hydroxyl in dextran and a dicarboxylic acid, a diacyl halide or a dicarboxylic anhydride containing an olefin double bond in a polar solvent to generate a carboxyl dextran derivative containing an olefin double bond; the carboxyl dextran derivative containing the olefin double bond is subjected to a thiol-alkene click reaction with a monovalent carboxylic acid containing a thiol group to generate the modified dextran with a dicarboxylic acid functional group. The T1 weighted iron-based contrast agent prepared by using the modified dextran as a template comprises iron oxide nanoparticles and the modified dextran; wherein the iron oxide nanoparticles are wrapped in the modified dextran, and the iron oxide nanoparticles and the modified dextran are connected through a chemical chelate bond. The T1 weighted iron-based contrast agent has small toxic and side effects and excellent magnetic resonance imaging performance.